AmacaThera, a clinical-stage biotechnology company specialising in drug delivery, announced a new pipeline program in collaboration with a leading global pharmaceutical company. Through this partnership, a single-injection, long-acting biologic will be developed using AmacaThera's advanced hydrogel delivery platform, AmacaGel™, in combination with the partner's therapeutic. 

Co-funded by both organisations, the initiative will leverage their complementary strengths and resources to accelerate the development of this innovative biologic.

"We are thrilled to collaborate on this promising venture. This partnership allows us to utilise AmacaThera's deep expertise in delivery to achieve success with novel biologics. Our core technology has been rigorously tested at AmacaThera and the University of Toronto with a wide range of therapeutics - including small molecules, biologics, and stem cells," said Molly Shoichet, Chief Scientific Officer at AmacaThera.

This announcement follows the recent release of Phase 1 data from AmacaThera's successful first-in-human study, which evaluated AmacaGel™ in combination with an anesthetic. The study generated valuable human data on both the core platform and its integration with a therapeutic payload.

Mike Cooke, Chief Executive Officer at AmacaThera, said, "This collaboration builds on our manufacturing know-how and human data collected from our hydrogel platform, enabling us to rapidly develop effective solutions to injectable delivery challenges." 

"Hydrogels have been widely researched, but what sets our platform apart is its broad compatibility with drug modalities, its simple, scalable and cost-effective manufacturing process, and its real-world human data," he added.

Raphael Hofstein, CQDM Board Member, said, "We have seen AmacaThera's technology progress from the laboratory to human trials, and this collaboration underscores industry's strong confidence in the AmacaThera platform." 

Mark Steedman, Senior Business Development Director at CQDM added, "We are excited  to have brought this collaboration together, and believe that due to the de-risked nature of the AmacaThera technology this project can advance rapidly and generate valuable data in a short period of time."

The partnership was facilitated by CQDM's Connect-Pharma series, which provides Canadian companies and academics the opportunity to connect with representatives from CQDM's global pharmaceutical members. CQDM is an organisation dedicated to fostering innovation and collaboration within the biopharmaceutical sector.